Avalo Therapeutics (NASDAQ:AVTX) Given Buy Rating at BTIG Research

BTIG Research restated their buy rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Tuesday,Benzinga reports. The firm currently has a $40.00 target price on the stock.

A number of other research analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Avalo Therapeutics in a report on Thursday, January 15th. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 target price on the stock. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $13.45 on Tuesday. The business’s fifty day moving average is $15.57 and its 200 day moving average is $15.78. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72. The company has a market capitalization of $248.96 million, a PE ratio of -2.35 and a beta of 0.84.

Insider Activity

In related news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the sale, the insider directly owned 3,622 shares in the company, valued at approximately $58,495.30. The trade was a 87.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.25% of the company’s stock.

Institutional Trading of Avalo Therapeutics

A number of large investors have recently added to or reduced their stakes in AVTX. BIT Capital GmbH purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth approximately $25,000. PFS Partners LLC grew its holdings in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares in the last quarter. Quadrature Capital Ltd bought a new stake in Avalo Therapeutics in the second quarter worth $55,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the second quarter worth $56,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Avalo Therapeutics during the third quarter valued at $143,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.